ScinoPharm Taiwan, Ltd. (TPE:1789)

Market Cap	16.76B
Revenue (ttm)	3.41B
Net Income (ttm)	339.35M
Shares Out	790.74M
EPS (ttm)	0.43
PE Ratio	49.40
Forward PE	55.79
Dividend	0.35 (1.67%)
Ex-Dividend Date	Jul 4, 2024

Volume	277,011
Average Volume	332,783
Open	21.00
Previous Close	21.00
Day's Range	21.00 - 21.50
52-Week Range	21.00 - 30.50
Beta	0.42
RSI	26.70
Earnings Date	May 5, 2025

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, India, the United States and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; outsourcing services. It offers CRAM services, such as chemistry skill, analytical...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 540
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1789

Financial Performance

In 2024, ScinoPharm Taiwan's revenue was 3.41 billion, an increase of 6.91% compared to the previous year's 3.19 billion. Earnings were 339.35 million, an increase of 18.22%.